Stent-anchored coil embolotherapy — Novel treatment procedure for huge pulmonary arterio-venous malformation in hereditary hemorrhagic telangiectasia

macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 2001;7:161–71. [16] Kim JY, van de Wall E, Laplante M, et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 2007;117:2621–37. [17] Liu Y, Zhang Y, Schmelzer K, et al. The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci U S A 2005;102:16747–52. [18] Pang W, Li N, Ai D, Niu XL, Guan YF, Zhu Y. Activation of peroxisome proliferatoractivated receptor-gamma downregulates soluble epoxide hydrolase in cardiomyocytes. Clin Exp Pharmacol Physiol 2011;38:358–64. [19] Wong SL, Huang Y. Targeting soluble epoxide hydrolase via peroxisome proliferatoractivated receptor gamma: a new therapeutic strategy for vascular complications. Clin Exp Pharmacol Physiol 2011;38:356–7. [20] Zhang Y,McGillicuddy FC, Hinkle CC, O'Neill S, Glick JM, Rothblat GH, et al. Adipocyte modulation of high-density lipoprotein cholesterol. Circulation 2010;121:1347–55. [21] Wu ZH, Zhao SP. Niacin promotes cholesterol efflux through stimulation of the PPARgamma-LXRalpha-ABCA1 pathway in 3T3-L1 adipocytes. Pharmacology 2009;84:282–7. [22] do Carmo JM, da Silva AA, Morgan J, JimWang YX, Munusamy S, Hall JE. Inhibition of soluble epoxide hydrolase reduces food intake and increases metabolic rate in obese mice. Nutr Metab Cardiovasc Dis 2010. [23] Sodhi K, Inoue K, Gotlinger KH, et al. Epoxyeicosatrienoic acid agonist rescues the metabolic syndrome phenotype of HO-2-null mice. J Pharmacol Exp Ther 2009;331:906–16. [24] Coats AJ. Ethical authorship and publishing. Int J Cardiol 2009;131:149–50.